Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2014 (2014), Article ID 797898, 8 pages
http://dx.doi.org/10.1155/2014/797898
Review Article

Therapeutic Potential of MicroRNA: A New Target to Treat Intrahepatic Portal Hypertension?

1Division of Gastroenterology and Hepatology, School of Medicine, Shanghai Institute of Digestive Disease, Renji Hospital, Shanghai Jiaotong University, 145 Shandong Middle Road, Shanghai, 200001, China
2Digestive Disease Laboratory, Department of Gastroenterology, School of Medicine, Xinhua Hospital, Shanghai Jiaotong University, Shanghai 200092, China

Received 18 November 2013; Revised 9 February 2014; Accepted 18 March 2014; Published 9 April 2014

Academic Editor: Wei Mike Liu

Copyright © 2014 Can-Jie Guo et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Intrahepatic portal hypertension accounts for most of the morbidity and mortality encountered in patients with liver cirrhosis, due to increased portal inflow and intrahepatic vascular resistance. Most treatments have focused only on portal inflow or vascular resistance. However, miRNA multitarget regulation therapy may potentially intervene in these two processes for therapeutic benefit in cirrhosis and portal hypertension. This review presents an overview of the most recent knowledge of and future possibilities for the use of miRNA therapy. The benefits of this therapeutic modality—which is poorly applied in the clinical setting—are still uncertain. Increasing the knowledge and current understanding of the roles of miRNAs in the development of intrahepatic portal hypertension and hepatic stellate cells (HSCs) functions, as well as their potential as novel drug targets, is critical.